Novo's Tresiba deadline in Germany looms; Scots back reimbursement for Sanofi's Toujeo; Reddy's teams up with Hatchtech on anti-lice med;

> Novo Nordisk ($NVO) said its long-acting basal insulin Tresiba would no longer be available in Germany as of next month; the Danish drugmaker had previously announced its intention to withdraw the product in a pricing dispute with German insurers. Report

> The Scottish Medicines Consortium gave its blessing to Sanofi's ($SNY) new basal insulin Toujeo, clearing the way for its routine use by the country's health service. Report

> Dr. Reddy's Laboratories ($RDY) inked a deal with the Australian drugmaker Hatchtech to develop and sell a prescription head lice product, Xeglyze, in a variety of countries, including the U.S. Report

> India's Sun Pharmaceutical saw shares rise on hopes for a periodic paralysis drug, Keveyis, which its U.S. unit Taro Pharmaceutical is preparing to launch. Report

> More pharma companies are jumping on the wearables bandwagon, with plans to distribute Fitbits and other devices to clinical trial participants and patients. Report

And Finally... A vaccine billionaire snapped up a former maharaja's Mumbai mansion for 7.5 billion rupees ($113 million) in the biggest-ever residential deal in India. Report